ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Bioorganic & Medicinal Chemistry Letters
Volume 17, Issue 8, 15 April 2007, Pages 2278-2280
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (130 K)

  E-mail Article   
  Add to my Quick Links   
Bookmark and share in 2collab (opens in new window)
Request permission to reuse this article
  Cited By in Scopus (0)
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.bmcl.2007.01.071    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2007 Elsevier Ltd All rights reserved.

Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker

Scott C. JeffreyCorresponding Author Contact Information, a, E-mail The Corresponding Author, Minh T. Nguyena, Ruth F. Mosera, Damon L. Meyera, Jamie B. Miyamotoa and Peter D. Sentera

aSeattle Genetics Inc., 21823 30th Drive S.E., Bothell, WA 98021, USA

Received 21 December 2006; 
revised 16 January 2007; 
accepted 18 January 2007. 
Available online 27 January 2007.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

The minor groove binder β-glucuronide drug-linker 3 was constructed from amino CBI 1 and determined to be a substrate for Escherichia coli β-glucuronidase (EC 3.2.1.31), resulting in facile drug release. Compound 3 was conjugated to mAbs cAC10 (anti-CD30) and h1F6 (anti-CD70) to give antibody-drug conjugates (ADCs) with potencies comparable to that of free drug 1. The ADCs were largely monomeric at intermediate loading levels (4–5 drug/mAb), in contrast to highly aggregated p-aminobenzylcarbamate dipeptide-based ADCs of 1 previously reported. Significant levels of immunologic specificity were observed with cAC10-3 by comparing antigen positive versus negative cell lines and binding versus non-binding control ADCs. The water soluble β-glucuronide linker is stable in plasma and effectively delivers drugs to target cells leading to potent cytotoxic activities.

Graphical abstract


Keywords: Aggregation; Antibody; Anti-CD30; Anti-CD70; β-Glucuronidase; β-Glucuronide; cAC10; Cancer; Conjugate; Delivery; Drug; Drug-linker; Minor groove binder; h1F6; Linker; Monoclonal; Release; Targeted

Article Outline

References



 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.